Pharmafile Logo
Pharmafocus logo
Advanced Search

RNAi therapeutics

Showing 1 posts of 1 posts found.

heart-2372134_640

ApoC3 targeted by Sirnaomics through its announced completion of IND-Enabling studies of safety and efficacy for STP125G with NHP Models

July 15, 2024
Research and Development Cardiology, RNAi therapeutics, Sirnaomics, biopharmaceutical, cardiovascular, investigational new drug

Sirnaomics, a biopharmaceutical company engaging in discovery and development of advanced RNAi therapeutics, has announced the completion of IND-enabling studies …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025